SEC Form 4 · accession 0001209191-16-115785
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marc Belsky
Officer — Senior Vice President and CFO
Period of report
Apr 22, 2016
Accepted (ET)
Apr 26, 2016 · 7:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 22, 2016 | M | 7,483 | $5.54 | A | 88,410 | D | |
| Common Stock | Apr 22, 2016 | M | 11,178 | $7.26 | A | 99,588 | D | |
| Common Stock | Apr 22, 2016 | M | 12,389 | $11.14 | A | 111,977 | D | |
| Common Stock | Apr 22, 2016 | M | 3,052 | $19.25 | A | 115,029 | D | |
| Common StockF2 | Apr 22, 2016 | S | 1,100 | $49.24 | D | 113,929 | D | |
| Common StockF3 | Apr 22, 2016 | S | 33,002 | $50.03 | D | 80,927 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F4 | $5.54 | Apr 22, 2016 | M | 7,483 | D | — | Jul 15, 2022 | Common Stock | 7,483 | 509 | D |
| Employee Stock Option (right to buy)F4 | $7.26 | Apr 22, 2016 | M | 11,178 | D | — | Jul 18, 2023 | Common Stock | 11,178 | 5,082 | D |
| Employee Stock Option (right to buy)F4 | $11.14 | Apr 22, 2016 | M | 12,389 | D | — | Aug 21, 2024 | Common Stock | 12,389 | 17,611 | D |
| Employee Stock Option (right to buy)F4 | $19.25 | Apr 22, 2016 | M | 3,052 | D | — | Aug 16, 2025 | Common Stock | 3,052 | 41,948 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on November 30, 2015.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.84 to $49.83, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.84 to $50.11, inclusive.
- F4This option is fully vested and immediately exercisable.